← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Phoenix Pharmalabs, Inc.
Providence, UT
$12,174,185
Total funding
6
Grants
Funding over time
peak $3.6M · FY2011–24$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,490,179 · 5
DOD$2,684,006 · 1
By mechanism
U01$8,683,509 · 1
—$2,684,006 · 1
R41$506,670 · 2
R43$300,000 · 2
Investigators at Phoenix Pharmalabs, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$3,623,079
U01 · FY2024 · DA
PRE-IND DEVELOPMENT OF PPL-103: A POTENT OPIOID ANALGESIC THAT IS SAFE, NON-ADDICTING, AND FREE OF OTHER DANGEROUS OPIOID SIDE EFFECTS$2,684,006
· FY2018 · Defense Health Agency
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,680,161
U01 · FY2022 · DA
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,380,269
U01 · FY2023 · DA
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder$319,983
R41 · FY2023 · DA
Unique Opioid Analgesics With No Addiction Liability or Dysphoria$200,000
R43 · FY2011 · DA
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy$186,687
R41 · FY2018 · DA
A Safe Analgesic Drug with Addiction Treatment Potential$100,000
R43 · FY2004 · DA